Cadrenal Therapeutics, Inc.
CVKD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001937993
No open-market purchases or sales by Cadrenal Therapeutics, Inc. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $379.6K in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Cadrenal Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 9 | 2 | −7 |
| Shares | 350.2K | 30 | −350.2K (−100.0%) |
| Value | $165.0K | $68 | −$164.9K (−100.0%) |
New holders (1)
Institutions that held Cadrenal Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Royal Bank of Canada | 25 | $0 | 0.00% |
Sold out (8)
Institutions that held Cadrenal Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Avantax Planning Partners, Inc. | 113,305 | $53.3K |
| Geode Capital Management, LLC | 61,554 | $28.9K |
| Renaissance Technologies LLC | 59,491 | $28.0K |
| Citadel Advisors LLC | 54,543 | $25.6K |
| Virtu Financial LLC | 24,737 | $12.0K |
| Two Sigma Securities, LLC | 15,858 | $7.45K |
| Biltmore Family Office, LLC | 11,000 | $5.17K |
| Tower Research Capital LLC (TRC) | 9,666 | $4.54K |